Our work reported for the first time that downregulation of AK4 can increase the protein stability and activity of p53 and explored a novel CHD7‐AK4‐AMPK‐p53 axis that plays an oncogenic role in CRC, providing several potential therapeutic targets of CRC. This evidence concerns the gene PRKAA1 and colorectal carcinoma.